Literature DB >> 35438415

MiR-30a-3p Suppresses the Growth and Development of Lung Adenocarcinoma Cells Through Modulating GOLM1/JAK-STAT Signaling.

Dongxiao Ding1, Yunqiang Zhang1, Xuede Zhang1, Ke Shi1, Wenjun Shang1, Junjie Ying1, Li Wang1, Zhongjie Chen1, Haihua Hong2.   

Abstract

A considerable amount of people succumbs to lung adenocarcinoma (LUAD) due to its high incidence and mortality. This study attempted to reveal the impacts of GOLM1 on LUAD. This work analyzed GOLM1 expression in LUAD and normal tissue and studied its prognostic value utilizing data from The Cancer Genome Atlas. RNA and protein levels were, respectively, determined utilizing qRT-PCR and western blot. Cell-aggressive behaviors were assessed employing Cell Counting Kit-8, scratch healing, and Transwell assays. The targetting relationship between GOLM1 and miR-30a-3p was assayed by dual-luciferase method. GOLM1 up-regulation in LUAD was found in TCGA and it was also a negative factor for survival in patients. GOLM1 overexpression promoted cell progression in LUAD. Down-regulated miR-30a-3p in LUAD was an upstream regulatory miRNA of GOLM1 in terms of molecular mechanism. Further, rescue assays illustrated that miR-30a-3p overexpression attenuated the GOLM1 facilitating impacts on LUAD progression. Finally, we proved that miR-30a-3p/GOLM1 regulated progression of LUAD cells via JAK-STAT pathway. Collectively, the inhibitory impacts of miR-30a-3p on LUAD growth may be mediated by GOLM1/JAK-STAT, which may contribute to the diagnosis of LUAD therapy and the development of therapeutic tools.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Development; GOLM1; JAK-STAT signaling; Lung adenocarcinoma; miR-30a-3p

Mesh:

Substances:

Year:  2022        PMID: 35438415     DOI: 10.1007/s12033-022-00497-x

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  37 in total

1.  The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma.

Authors:  Mao Qixing; Xu Juqing; Wang Yajing; Dong Gaochao; Xia Wenjie; Shi Run; Wang Anpeng; Xu Lin; Jiang Feng; Wang Jun
Journal:  Tumour Biol       Date:  2017-04

2.  Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro.

Authors:  Rong Li; Yuqing Lou; Weiyan Zhang; Qianggang Dong; Baohui Han
Journal:  Tumour Biol       Date:  2014-08-03

Review 3.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

4.  GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

Authors:  Shuanzeng Wei; Thomas A Dunn; William B Isaacs; Angelo M De Marzo; Jun Luo
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

5.  An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.

Authors:  Lishuang Qi; Yang Li; Yuan Qin; Gengen Shi; Tianhao Li; Jiasheng Wang; Libin Chen; Yunyan Gu; Wenyuan Zhao; Zheng Guo
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

Review 6.  Recent advances of GOLM1 in hepatocellular carcinoma.

Authors:  Jiuliang Yan; Binghai Zhou; Hui Li; Lei Guo; Qinghai Ye
Journal:  Hepat Oncol       Date:  2020-06-29

7.  LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.

Authors:  Xia Zhao; Xiaoyou Li; Leilei Zhou; Jie Ni; Wenyue Yan; Rong Ma; Jianzhong Wu; Jifeng Feng; Ping Chen
Journal:  Cancer Sci       Date:  2018-09-02       Impact factor: 6.716

8.  GP73, a novel Golgi-localized protein upregulated by viral infection.

Authors:  R D Kladney; G A Bulla; L Guo; A L Mason; A E Tollefson; D J Simon; Z Koutoubi; C J Fimmel
Journal:  Gene       Date:  2000-05-16       Impact factor: 3.688

9.  Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.

Authors:  Ruyang Zhang; Chao Chen; Xuesi Dong; Sipeng Shen; Linjing Lai; Jieyu He; Dongfang You; Lijuan Lin; Ying Zhu; Hui Huang; Jiajin Chen; Liangmin Wei; Xin Chen; Yi Li; Yichen Guo; Weiwei Duan; Liya Liu; Li Su; Andrea Shafer; Thomas Fleischer; Maria Moksnes Bjaanæs; Anna Karlsson; Maria Planck; Rui Wang; Johan Staaf; Åslaug Helland; Manel Esteller; Yongyue Wei; Feng Chen; David C Christiani
Journal:  Chest       Date:  2020-02-28       Impact factor: 9.410

10.  Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Authors:  Matteo Santoni; Daniel Y Heng; Sergio Bracarda; Giuseppe Procopio; Michele Milella; Camillo Porta; Marc R Matrana; Giacomo Cartenì; Simon J Crabb; Ugo De Giorgi; Umberto Basso; Cristina Masini; Fabio Calabrò; Maria Giuseppa Vitale; Daniele Santini; Francesco Massari; Luca Galli; Giuseppe Fornarini; Riccardo Ricotta; Sebastiano Buti; Paolo Zucali; Orazio Caffo; Franco Morelli; Francesco Carrozza; Angelo Martignetti; Alain Gelibter; Roberto Iacovelli; Alessandra Mosca; Francesco Atzori; Nuno Vau; Lorena Incorvaia; Cinzia Ortega; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Vittorio Paolucci; Jeffrey Graham; Erin Pierce; Sarah Scagliarini; Pierangela Sepe; Elena Verzoni; Sara Merler; Mimma Rizzo; Giulia Sorgentoni; Alessandro Conti; Francesco Piva; Alessia Cimadamore; Rodolfo Montironi; Nicola Battelli
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.